FDA Approval Summary: Olaparib Monotherapy or in Combination with Bevacizumab for the Maintenance Treatment of Patients with Advanced Ovarian Cancer

On December 19, 2018, the U.S. Food and Drug Administration (FDA) granted approval to olaparib monotherapy for first‐line maintenance treatment of BRCA‐mutated (BRCAm) advanced ovarian cancer and, on May 8, 2020, expanded the indication of olaparib to include its use in combination with bevacizumab...

תיאור מלא

שמור ב:
מידע ביבליוגרפי
הוצא לאור ב:Oncologist
Main Authors: Arora, Shaily, Balasubramaniam, Sanjeeve, Zhang, Hui, Berman, Tara, Narayan, Preeti, Suzman, Daniel, Bloomquist, Erik, Tang, Shenghui, Gong, Yutao, Sridhara, Rajeshwari, Turcu, Francisca Reyes, Chatterjee, Deb, Saritas‐Yildirim, Banu, Ghosh, Soma, Philip, Reena, Pathak, Anand, Gao, Jennifer J., Amiri‐Kordestani, Laleh, Pazdur, Richard, Beaver, Julia A.
פורמט: Artigo
שפה:Inglês
יצא לאור: John Wiley & Sons, Inc. 2020
נושאים:
Regulatory Issues: FDA
גישה מקוונת:https://ncbi.nlm.nih.gov/pmc/articles/PMC7794199/
https://ncbi.nlm.nih.gov/pubmed/33017510
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/onco.13551
תגים: הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!

פריטים דומים